<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>
    <title>130M on Tenu Tech Brief</title>
    <link>https://cluster-site.onrender.com/tags/130m/</link>
    <description>Recent content in 130M on Tenu Tech Brief</description>
    <generator>Hugo -- 0.146.0</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 25 Feb 2026 07:59:11 +0000</lastBuildDate>
    <atom:link href="https://cluster-site.onrender.com/tags/130m/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Headache Startup Slate Medicines Lands $130M to Bring Novel Migraine Drug Into the Clinic</title>
      <link>https://cluster-site.onrender.com/posts/headache-startup-slate-medicines-lands-130m-to-bring-novel-migraine-drug-into-the-clinic/</link>
      <pubDate>Tue, 24 Feb 2026 19:13:57 +0000</pubDate>
      <guid>https://cluster-site.onrender.com/posts/headache-startup-slate-medicines-lands-130m-to-bring-novel-migraine-drug-into-the-clinic/</guid>
      <description>• Slate Medicines&amp;rsquo; antibody drug is designed to block PACAP, a protein associated with migraines. • The Phase 1-ready asset was licensed from China-based DartsBio Pharmaceuticals.</description>
    </item>
  </channel>
</rss>
